AU2016285727B9 - Biomarkers for nanoparticle compositions - Google Patents

Biomarkers for nanoparticle compositions Download PDF

Info

Publication number
AU2016285727B9
AU2016285727B9 AU2016285727A AU2016285727A AU2016285727B9 AU 2016285727 B9 AU2016285727 B9 AU 2016285727B9 AU 2016285727 A AU2016285727 A AU 2016285727A AU 2016285727 A AU2016285727 A AU 2016285727A AU 2016285727 B9 AU2016285727 B9 AU 2016285727B9
Authority
AU
Australia
Prior art keywords
mtor
individual
activating aberration
cancer
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016285727A
Other languages
English (en)
Other versions
AU2016285727A1 (en
AU2016285727B2 (en
Inventor
Neil P. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of AU2016285727A1 publication Critical patent/AU2016285727A1/en
Publication of AU2016285727B2 publication Critical patent/AU2016285727B2/en
Application granted granted Critical
Publication of AU2016285727B9 publication Critical patent/AU2016285727B9/en
Priority to AU2021290200A priority Critical patent/AU2021290200B2/en
Priority to AU2024204661A priority patent/AU2024204661A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2016285727A 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions Active AU2016285727B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021290200A AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions
AU2024204661A AU2024204661A1 (en) 2015-06-29 2024-07-05 Biomarkers for nanoparticle compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186309P 2015-06-29 2015-06-29
US62/186,309 2015-06-29
PCT/US2016/040196 WO2017004264A1 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021290200A Division AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions

Publications (3)

Publication Number Publication Date
AU2016285727A1 AU2016285727A1 (en) 2018-02-01
AU2016285727B2 AU2016285727B2 (en) 2021-09-23
AU2016285727B9 true AU2016285727B9 (en) 2021-09-30

Family

ID=57609078

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016285727A Active AU2016285727B9 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions
AU2021290200A Active AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions
AU2024204661A Pending AU2024204661A1 (en) 2015-06-29 2024-07-05 Biomarkers for nanoparticle compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021290200A Active AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions
AU2024204661A Pending AU2024204661A1 (en) 2015-06-29 2024-07-05 Biomarkers for nanoparticle compositions

Country Status (10)

Country Link
US (3) US20180177771A1 (https=)
EP (1) EP3313381A4 (https=)
JP (4) JP2018527308A (https=)
KR (2) KR20240144442A (https=)
AU (3) AU2016285727B9 (https=)
CA (1) CA2990703C (https=)
HK (1) HK1254398A1 (https=)
IL (2) IL312318A (https=)
MX (2) MX2017016519A (https=)
WO (1) WO2017004264A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
WO2019140257A1 (en) * 2018-01-11 2019-07-18 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing and treating prostate cancer
IL277402B1 (en) * 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
TW202015659A (zh) * 2018-05-22 2020-05-01 美商亞伯辛生物科學有限責任公司 用於治療肺高血壓之方法及組合物
CN111187834B (zh) * 2019-01-08 2021-01-22 中国科学院上海营养与健康研究所 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
KR102936433B1 (ko) * 2019-03-19 2026-03-09 아브락시스 바이오사이언스, 엘엘씨 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
EP4058000A4 (en) * 2019-11-11 2024-02-28 Abraxis BioScience, LLC BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
EP4225949A1 (en) * 2020-10-06 2023-08-16 The Regents of the University of Colorado, a body corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
WO2022186673A1 (ko) * 2021-03-05 2022-09-09 전남대학교산학협력단 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘
WO2024215799A1 (en) * 2023-04-11 2024-10-17 Leapfrog Bio, Inc. Pi3k inhibitors for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2801314A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
KR102759126B1 (ko) * 2010-12-30 2025-01-24 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
EP2971122B1 (en) * 2013-03-15 2020-08-26 Memorial Sloan Kettering Cancer Center Biomarkers for response to rapamycin analogs
JP2018521058A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス, エルエルシー ナノ粒子mTOR阻害剤併用治療を使用して固形腫瘍を処置する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. G. MALOUF ET AL, Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network, ANNALS OF ONCOLOGY, NL, (2010-2-12), vol 21, no 9, ISSN 0923-7534, pg1834-1838 *
INOKI, K et al., "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling", Nat Cell Biol, (2002-08-12), vol. 4, pages 648–657 *
JANKU, F et al., "Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors", Cell Reports., (2014-01-30), vol. 6, no. 2, pages 377 - 387 *

Also Published As

Publication number Publication date
IL256326A (en) 2018-02-28
KR20240144442A (ko) 2024-10-02
US20180177771A1 (en) 2018-06-28
JP2025097987A (ja) 2025-07-01
KR102708679B1 (ko) 2024-09-24
EP3313381A4 (en) 2019-02-27
CA2990703C (en) 2024-04-30
AU2016285727A1 (en) 2018-02-01
JP2023071656A (ja) 2023-05-23
MX2017016519A (es) 2018-08-16
AU2016285727B2 (en) 2021-09-23
AU2024204661A1 (en) 2024-07-25
CA2990703A1 (en) 2017-01-05
JP2018527308A (ja) 2018-09-20
EP3313381A1 (en) 2018-05-02
AU2021290200B2 (en) 2024-05-02
WO2017004264A1 (en) 2017-01-05
KR20180019230A (ko) 2018-02-23
US20230080409A1 (en) 2023-03-16
MX2023013010A (es) 2023-11-15
HK1254398A1 (zh) 2019-07-19
IL312318A (en) 2024-06-01
US20250152563A1 (en) 2025-05-15
AU2021290200A1 (en) 2022-01-20
IL256326B2 (en) 2024-09-01
IL256326B1 (en) 2024-05-01
JP2021169457A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
AU2021290200B2 (en) Biomarkers for nanoparticle compositions
US12133844B2 (en) Methods of treating epithelioid cell tumors
JP2018527308A5 (https=)
US20240009323A1 (en) Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
HK40074948A (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HK40074948B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HK1247094B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)